Current Report Filing (8-k)
April 19 2022 - 04:32PM
Edgar (US Regulatory)
0000315545 false 0000315545 2022-04-19
2022-04-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported):
April 19, 2022
PROVECTUS BIOPHARMACEUTICALS, INC.
(Exact
name of registrant as specified in charter)
|
Delaware |
|
001-36457 |
|
90-0031917 |
|
(State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
|
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
10025 Investment Drive,
Suite 250,
Knoxville,
Tennessee
37932
(Address
of Principal Executive Offices) (Zip Code)
(866)
594-5999
(Registrant’s
Telephone Number, Including Area Code)
N/A
(Former
Name or Former Address, if Changed Since Last Report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2
below):
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
| |
|
|
☒ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: None
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
|
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
On
April 19, 2022, Provectus Biopharmaceuticals, Inc. (the “Company”)
issued a press release announcing that it has filed a preliminary
proxy statement with the Securities and Exchange Commission (“SEC”)
in connection with its 2022 Annual Meeting of Stockholders (the
“Annual Meeting”) to, among other things, seek stockholder approval
of a reverse stock split proposal and authorized share reduction
proposal. The Annual Meeting is scheduled to be held on June 22,
2022.
Attached
hereto as Exhibit 99.1, and incorporated herein by reference, is a
copy of the press release.
Other
Information
The
Company and its directors, executive officers, and advisors may be
deemed to be participants in the solicitation of proxies in
connection with the proposals to be considered at the Annual
Meeting. Stockholders may obtain additional information regarding
the interests of those participants by reading the Company’s
preliminary proxy statement filed with the SEC on April 19, 2022,
and, when they become available, the Company’s definitive proxy
statement and other definitive proxy materials, and the Company’s
Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, as
filed with the SEC.
A
notice of internet availability of proxy materials with
instructions for accessing the definitive proxy statement will be
mailed to stockholders as of the record date of April 25, 2022.
Stockholders may obtain free copies of the preliminary proxy
statement and the Company’s other SEC filings electronically by
accessing the SEC’s home page at http://www.sec.gov. Copies can
also be obtained, free of charge, upon written request to the
Company, Attn: Secretary, 10025 Investment Drive, Suite 250,
Knoxville, Tennessee 37932, (866) 594-5999.
|
Item
9.01. |
Financial
Statements and Exhibits. |
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| Date:
April 19, 2022 |
|
| |
|
| |
PROVECTUS
BIOPHARMACEUTICALS, INC. |
| |
|
|
|
By: |
/s/
Heather Raines |
| |
|
Heather
Raines |
| |
|
Chief
Financial Officer (Principal Financial Officer) |
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Sep 2022 to Oct 2022
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Oct 2021 to Oct 2022
